WARREN, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, has announced financial results for the fiscal quarter ending September 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Studies Uncover Hidden Urologic Risks—How Water, Chemicals and Everyday Exposures Impact Urinary Health - April 26, 2025
- RAINN Statement on the Passing of Virginia Giuffre - April 26, 2025
- Studies Unveil Groundbreaking Advances in Prostate Cancer: From AI-Driven Detection to Non-Invasive Testing - April 26, 2025
